, and all were confirmed. Nearly half of the 260 genes were functionally categorized as encoding growth-regulatory proteins. Of the 104 with described growth-regulatory function, 71 were induced more than three times by 500 U/ml and twice by 50 U/ml IFN-b, and 48 of these were new ISGs. Included in this latter category were tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), XIAP-associated factor 1 (XAF1), galectin 9, a cyclin E binding protein, amphiphysin 1, MyD88, and several ubiquitin pathway genes. The diversity of stimulated genes suggests the full therapeutic potential of IFN regulation of gene expression has yet to be realized. 745 
INTRODUCTION I
NTERFERONS (IFNS) ARE MULTIFUNCTIONAL CYTOKINES, defined on the basis of viral inhibition and classified into structurally and antigenically discrete families. IFN-g is produced in substantial amounts by activated T cells, whereas the IFNs activated by viruses or inducers in nonlymphoid cells are IFNa and IFN-b. Human IFN-b differing from IFN-a in primary amino acid sequence by approximately 70%, is represented as a single copy gene that is expressed predominantly in nonhematopoietic cells. (1) In contrast, the IFN-a prototype gene has become amplified to high copy numbers, comprising up to 30 distinct loci in certain mammals. (2) (3) (4) (5) (6) (7) Both IFN-a and IFN-b bind to the same heterodimeric receptor on cell surfaces. (7, 8) Despite a signal transduction pathway with common elements, distinct cellular and clinical effects have been defined for IFNa and IFN-b. (7) (8) (9) (10) (11) (12) The greater antiproliferative and apoptosisinducing effects of IFN-b in vitro have been prominent when compared on a mass or an antiviral unit basis with IFN-a2. (9) (10) (11) (12) Underlying these differences in biologic effects of IFN-a and IFN-b must be differential expression of the protein products of IFN-stimulated genes (ISGs). Although some ISGs were identified initially on the basis of their functions, others were identified only as differentially regulated mRNA species. (13) (14) (15) IFN-b is more potent in vitro than IFN-a at inhibiting cell proliferation and apoptosis, but the ISG determinants of this difference are unknown. (10, 12) Studies have demonstrated that IFNs can, as single agents, induce apoptosis in some tumor cell types, including melanomas. (12, (16) (17) (18) (19) For example, treatment of WM9 melanoma cells with IFN-b, but not with IFN-a2, caused a potent apoptotic effect. (12) Thus, we postulated that this cell line would be useful to assess differences in ISGs regulated by IFN-a2 and IFN-b that are potentially associated with the proapoptotic effects of IFN-b.
MATERIALS AND METHODS

Cell lines and RNA isolation
Cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). WM9 and WM35 melanoma cells (provided by M. Herlyn, Wistar Institute, PA) used for gene array analyses were confirmed mycoplasma free prior to use. For the U95A studies (Affymetrix human genome U995A array; 12,683 probe sets), WM9 and WM35 cells were left untreated or treated for 2, 8, or 18 h with 500 U/ml IFN-a (Intron A, Schering-Plough, Inc., Kenilworth, NJ; specific activity 2 3 10 8 U/mg protein) or IFN-b (REBIF, Serono, Inc., Rockland, MA; specific activity 2 3 10 8 U/mg protein) prior to RNA extraction. For the U133A study (Affymetrix human genome U133A array; ,45,000 probe sets), WM9 cells were left untreated or treated with either 50 U/ml or 500 U/ml IFNb for 16 h. For all studies, RNA was isolated using Trizol reagent (Invitrogen, San Diego, CA).
Gene array studies
For U95A gene array analyses, equivalent total cellular RNA aliquots (40 mg each) from untreated or IFN-a-treated or IFNb-treated cells at each time point were pooled. Poly A 1 RNA was isolated from 100 mg of the pooled total cellular RNA using the Oligotex mRNA kit (Qiagen, Chatsworth, CA). Reverse transcription reactions (1.5 mg poly A 1 RNA/sample) were performed using the Superscript Choice System (Invitrogen) according to the manufacturer's instructions. Double-stranded cDNA (1 mg) was transcribed in vitro into cRNA using the Enzo Bioarray RNA transcript labeling kit (Affymetrix, Inc., Santa Clara, CA). Biotinylated CTP (Biotin-11-CTP) and UTP (Biotin-16-UTP) were incorporated into the cRNA during synthesis. The cRNA was purified from unincorporated NTPs using RNeasy spin columns as recommended by the manufacturer (Qiagen). Concentration of purified cRNA was estimated by spectrophotometric analysis, and size distribution was assessed by gel electrophoresis. Approximately 20 mg cRNA was fragmented in fragmentation buffer (40 mM Tris-acetate, pH 8.1, 100 mM potassium acetate, 30 mM magnesium acetate) at 94°C for 35 min. Fragmented cRNA was added to gene chips in hybridization solution and hybridized at 40°C for 16 h. After this, arrays were washed, stained with streptavidin-phycoerythrin, washed again, and scanned. Data were analyzed using Microarray Suite software and Data Mining Tools software (both from Affymetrix, Inc.). Samples for the U133A study were processed identically, except that 10 mg total cellular RNA was used as the starting material. The U95A gene array (Affymetrix, Inc.) contains 12,683 gene probe sets, and the U133A gene array (Affymetrix, Inc.) contains almost 45,000 oligonucleotide probes with 22,000 distinct genes represented.
Northern blot and RT-PCR
Verification of novel ISG induction by IFN was assessed using Northern blotting or reverse transcriptase-coupled polymerase chain reaction (RT-PCR). For RT-PCR studies, total cellular RNA (2 mg) was reverse transcribed using Moloney murine leukemia virus (MMLV) RT (Promega, Madison, WI) and random hexamer primers (42°C for 60 min). One tenth of the RT reaction was subjected to PCR analysis using primer pairs specific for each ISG. A typical PCR reaction was carried out for 25 cycles with a 55°C annealing temperature. PCR products were resolved on 1% agarose gels, and bands were visualized with ethidium bromide. For Northern blot studies, 20 mg total cellular RNA from cells left untreated or treated with 500 IU/ml IFN-a2 or IFN-b for various lengths of time was resolved on a denaturing agarose gel, transferred to nylon membrane, and hybridized with 32 P-labeled specific cDNA probes.
Quantitative real-time PCR
Primers for SP100, TSG6, AIPC, cyclin E, UBE2L6, USP18, and GAPDH were purchased from Applied Biosystems, Inc. (Foster City, CA) and used according to the manufacturer's instructions with Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems, Inc). Briefly, cells were incubated 6 with 500 IU/ml IFN-a2 or IFN-b for the treatment times indicated. RNA was isolated with Trizol following the manufacturer's protocol. RNA was converted to cDNA, and 200 ng cDNA was used with the Universal PCR Master Mix on an ABI Prism Sequence Detection Instrument 7700. After 40 cycles, data reduction was performed with Sequence Detection System software (Applied Biosystems Inc.).
RESULTS
Comparison of effects of IFN-a2 and IFN-b
After 96 h of continuous exposure to IFN-b, WM9 cells exhibited morphologic changes characteristic of apoptosis, with an overall loss in cell numbers. (12) In contrast to the changes observed with IFN-b, IFN-a2 did not induce apoptosis in WM9 cells, even at doses 100-fold higher than those required for IFNb-induced apoptosis (Fig. 1A) . Antiviral potency is the basis for definition of the biologic activity of an IFN preparation. To affirm the activity measure provided by the manufacturer, the antiviral activity of both IFN-a2 and IFN-b was reassessed. Equivalence in antiviral activities of IFN-a2 and IFN-b, based on the manufacturer's label titer, was confirmed (Fig. 1B) . Thus, it was postulated that downstream effects of IFNs must cause induction of specific ISGs that were responsible for the IFN-b-restricted effects.
As a preliminary study, cRNA prepared from a melanoma cell line, WM9, was assessed using an array (Affymetrix Hu 6800) containing approximately 5000 human genes. This analysis identified previously unknown ISGs, some of which could be associated with apoptosis (data not shown). To further define these genes, two different melanomas cell lines, WM9 and WM35, were hybridized to an oligonucleotide gene array containing over 10,000 human genes (Affymetrix U95). WM35 cells were inhibited in proliferation but did not undergo apoptosis after treatment with either IFN-a2 or IFN-b. (12) They thus served as a control to identify genes specifically involved in apoptosis in WM9 cells.
Although many known ISGs have been induced within 6 h of IFN stimulation, (20) expression can persist for many hours. For these studies, RNA was isolated from cells left untreated or treated with 500 U/ml IFN-a2 or IFN-b at 2, 8, and 18 h. Equimolar RNA from each point for each treatment was pooled prior to generation of the cRNA for the 8 Affymetrix U95A oligonucleotide gene array hybridization experiments. Northern blot analyses confirmed that this strategy did not dilute significantly the signal of a known ISG, RIG-G (cig49) (data not shown).
To be called an ISG, gene induction (WM9 and WM35 cells) on the U95 array had to meet the following criteria: expression of individual genes had to be scored as "increased" relative to untreated controls by the Microarray Suite (v. 5.0) software (p , 0.005), exhibit a minimum of $2.3 times induction over controls, be scored as "present" by the Affymetrix Microarray Suite software after IFN, and be increased in at least two of the comparisons (both IFNs or both cell lines). Using these relatively rigorous criteria, of 48 previously known ISGs present on the gene array, 42 of 48 were identified as increased by IFNb in WM9 or WM35 cells (Table 1 ; data not shown). Only 6 known IFN-a2-stimulated or IFN-b-stimulated genes present on the array (PKR, Ly6, PML-1, GTP cyclohydrolase, b 2 m, and IRF-2) did not meet the defined criteria. Fold increases in gene expression were almost always less in RNA derived from IFN-a2-treated cells than in that from IFN-b (Table 1) .
Using the U95A Affymetrix array, 30 new ISGs induced by IFN-a and IFN-b were identified (see examples in Table 1 ). These ISGs were all subsequently confirmed by Northern blots, semiquantitative or quantitative RT-PCR, or a second array. The distinction between a known and a new ISG was not always absolute. Some ISGs, such as the serine protease C1 inhibitor, have been described previously as IFN-g induced, and others were genes not defined as IFN responsive at the outset of these studies subsequently identified functionally. (20) (21) (22) (23) (24) Direct comparison of the gene modulatory potential of IFNa and IFN-b was possible for the 73 new and previously identified ISGs identified on these arrays (Table 1) . For the 146 comparisons in the WM9 and WM35 cell lines, IFN-b potency was $ IFN-a2 for induction of gene expression in 137 instances (95%). In 23 of these comparisons, the effectiveness of IFN-b in augmenting gene expression was $2 times more than occurred with IFN-a2. Several genes showed a markedly greater response in both cell lines to IFN-b, including cig5 (viperin), cig49, ISG54, TLR3, CXCL10, and TRAIL (Table 1) .
Most known and novel ISGs were induced by both IFNs to a similar extent in the apoptosis-sensitive WM9 and apoptosisresistant WM35 cells (Table 1) . However, some of the potentially apoptosis-related genes were implicated as specific to one or the other cell line. Galectin-9 was identified as an ISG in WM9 but not WM35 (Table 1) on the array, and RT-PCR studies confirmed this (Fig. 2) . Another ISG, K12, was upregulated strongly in WM9 but weakly in WM35 (Table 1) and not at all in some nonmelanoma cell lines (Fig. 3A) . TRAIL induction was similarly higher in WM9 compared with WM35 (Fig. 3B) . Conversely, ISG p78 was more markedly upregulated in WM35.
Identification of ISGs on U133A gene array
In order to develop a complete list of ISGs induced in WM9 melanoma cells for association with growth-regulatory effects and apoptosis, an analysis was undertaken after treatment with 
Confirmation by Northern Blot and RT-PCR of kinetics of induction of apoptosis-related ISGs
Other microarray studies have suggested the potential for false positive designation from array criteria. (25) Thus, to further confirm the validity of the established criteria, RNA was assessed using Northern blot or RT-PCR for 28 of the newly identified ISGs from the U133 array, with a focus on those that might function as antiproliferative or apoptosis-related proteins or as products of tumor suppressor genes ( Table 2) . Among these were galectin-9, a b-galactoside binding lectin implicated in apoptosis (26, 27) (Fig. 2) , K12, a cell surface transmembrane protein (28) (Fig. 3) , legumain, a cysteine protease with a caspase-related catalytic site (29) (Fig. 4A) , and MyD88, an adaptor signaling molecule with a death domain involved in medi- h, after which total cellular RNA was isolated. TRAIL mRNA levels were determined using RT-PCR with TRAIL-specific primers. As an internal control, GAPDH mRNA levels were assessed using the same RT reactions used in the TRAIL mRNA amplification. (30, 31) (Fig. 4B ). Quantitative PCR was used to assess comparative magnitude and kinetics of augmentation by IFN-a2 and IFN-b for genes SP100, a promyelocytic leukemia (PML)-associated gene, (32) TNFstimulated gene 6, (33, 34) augmented in prostate carcinoma (AIPC) gene, (35) a cyclin-E and Myc-associated protein, (36) ubiquitin E 2 -like protein (UBEL-2), (37) and a ubiquitin-specific protease (23, 38) (Fig. 5) . In all instances, induction was confirmed by both IFN-a2 and IFN-b (Figs. 3, 4 , 5, and 6), but in almost every instance, the signal for IFN-b was 2-4 times stronger and more sustained at 18 h than that for IFN-a2. The oligonucleotide array results had indicated that none of these genes had a greater response to IFN-a2 as compared with IFN-b (Table 1) , a contention confirmed in assessments by Northern blots or RT-PCR (Figs. 2, 3 , and 4; data not shown).
IFN-STIMULATED GENES IN
Expression of several genes was assessed over 42 h after stimulation with a single bolus of 500 IU/ml IFN-a2 or IFNb. Assessment of the kinetics of induction of these genes further enabled categorization of the different ISGs as those that peak at early (e.g., 8 h), mid (18 h), or late (36 or 42 h) points after IFN stimulation (Fig. 6) . However, in all instances, no signal was obtained at 8 h that was not present at 18 h, suggesting all transcriptionally induced genes had been identified in the 16 h assessment on the U133A array. The results of these confirming studies further substantiated the selection criteria used for array analysis and the greater potency of gene induction by IFN-b.
Functional classification
To further identify genes potentially involved in apoptosis, growth, maintenance, or tumor suppression, the 260 ISGs derived from the 22,000 gene array study were analyzed for function using Source (source.stanford.edu). (39) Of the 260 genes, 103 (40%) were augmented .2 times and were predicted to potentially play some role in cell growth, maintenance, or apoptosis based on Source or the literature. Of these, 71 were augmented $3 times by 500 U IFN-b and $2 times by 50 U IFN-b (Table 2 ). Previously unknown ISGs accounted for 48/71 (67%) of these. Although functions of many of these genes may also influence other cellular processes, this long list of highly induced ISGs further confirms that cell growth regulation and death, either directly or indirectly, are an integral part of physiologic and pharmacologic responses to IFNs.
DISCUSSION
Using an oligonucleotide array with .10,000 genes and a relatively rigorous analysis of expression, 73 genes were identified as induced by IFN-a and IFN-b. Of these, 43 represented well-recognized ISGs, and 30 were newly identified ISGs. A second independent gene array study with a larger, 22,000 gene array identified 260 genes as upregulated by both 50 and 500 U/ml IFN-b in WM9 melanoma cells. Of these, 209 were previously unrecognized ISGs. Many of these latter genes were not represented on earlier generation arrays.
Criteria previously used for designation of an ISG proved very useful. (22) They were, however, refined to reduce the frequency potential false positives. Criteria were confirmed using of Northern blot or RT-PCR and resulted in a true positive call in all 28 instances so assessed. The criteria resulted, however, in the elimination of a few genes that were true ISGs (20, 25, 40, 41) (unpublished observations). This total of 260 ISGs out of 33,000 genes profiled, or roughly 1% of the represented genes, was a lower percentage than previously estimated. (40) Cells of varied histogenesis differ qualitatively and quantitatively from WM9 and WM35 melanoma in induction of ISGs induced (40) (41) (42) (unpublished observations). Most other new ISGs, identified as induced by IFN-a2 in other melanoma cell lines, (22) were either not present on our arrays or could not be confirmed as induced. Furthermore, in vivo ISGs have proven to be among the most physiologically variable of several gene clusters. (43) Despite equivalence in antiviral units added to cells for evaluation of induced genes (Fig. 1) , essentially every ISG was upregulated to a greater extent by IFN-b. Prior gene array studies of HT1080 fibrosarcoma and primary vascular endothelial cells also found genes to be more strongly induced by IFNb. (40, 42) At low IFN concentrations, these differences can be more substantial. (42) TRAIL gene was induced more strongly (.3-fold) with prolonged kinetics by 14 IFN-b compared with IFN-a2 ( Fig. 3B and Table 2 ), emphasizing that IFN-a and IFN-b have different biologic effects despite binding a common receptor. (12) Greater affinity for the type I receptor complex, involvement of other receptor components, activation of additional signaling pathways must mediate the different biologic effects of IFN-b and IFN-a2. Total cellular RNA was isolated and analyzed by Northern blotting using a legumain or MyD88 cDNA probe. The blot was stripped and reprobed with GAPDH to control for differences in RNA loading.
The new generation of Microarray Suite and Data Mining Tools software did not identify genes that were scored consistently as downregulated following IFN treatment when the U95A and U133A array experiments were compared. Among the genes scored as decreased on both array studies were malate dehydrogenase, topoisomerase II b, and integrin aE precursor, occur. Stat1 plays both IFN-dependent and IFN-independent roles in suppressing c-myc transcription and could be responsible in part for reported c-myc and c-met downregulation. (46, 47) Viruses can cause downregulation of expression of Stat1 and some ISGs. (47, 48) IRF-2 has also been shown to repress transcription and may contribute to the eventual cessation of an IFN response, (49) but in the short-term treatments employed here, no repressive effects were observed.
Apoptosis induced by IFN-b is an effect distinct from that caused by IFN-a2 in melanoma cells. No significant apoptosis was caused by IFN-a2 except at supraphysiologic concentrations (2500 U/ml). Induction of apoptosis in melanoma by IFNb was mediated, at least in part, by TRAIL. (12) Neutralization of TRAIL blocked IFN-b-induced apoptosis, demonstrating that it was necessary, although not necessarily sufficient, to mediate apoptotic responses. (12) TRAIL was also induced by IFNs in T cells and dendritic cells (20, 21) and, thus, appears to be an important mediator of IFN action. The Fas/FasL system has been implicated in mediating apoptosis in hematopoietic cells exposed to IFN-g. (18, 50) FasL was not expressed constitutively in melanoma, (51) and neither FasL nor Fas transcripts were upregulated by IFN-a or IFN-b in the WM9, WM35, or A375 cells examined in these gene array studies or by using RNase protection analysis. (12) Thus, this death ligand would not appear important in IFN-mediated cell death in melanoma. Other ISGs have been implicated in IFN-dependent sensitization of cells to apoptosis, including X-linked inhibitor of apoptosis (XIAP)-associated factor 1 (XAF1), (52) which was induced much more strongly by IFNs in the apoptosis-sensitive WM9 than in the WM35 cells, which do not undergo apoptosis in response to IFN as a single agent (Table 1) . p53, recently implicated to have a functional role in IFN signaling, (53) was not identified as an ISG in any of our experiments.
Among the new ISGs identified was galectin-9 ( Fig. 2) . Galectin-9 is a galactosidase-binding lectin that has been implicated in apoptosis, but its role in this process is poorly understood. (26, 27, 54) Galectin-9 induced apoptosis in various hematopoietic cells and in melanomas but failed to induce apoptosis in some other cell types. (27, 54) Some of the approximately 20 other galectin isoforms may play a role in apoptosis in addition to effects on cell adhesion, immunity, inflammation, and cancer. (54) Galectin-9 expression was robustly upregulated in the WM9 but not in the WM35 cells, and the potential role for galectin-9 in IFN-induced apoptosis in WM9 cells is currently under evaluation.
K12 (known also as SECTM1) binds CD7 on the surface of T, natural killer (NK), and pre-B cells. (28) As it can downregulate growth signals and has a transmembrane domain, (55) it is not unreasonable to speculate that its 6-fold higher expression in WM9 cells, compared with WM35 cells, might play a role in growth control. Both constitutive and IFN-induced expression 16 occurred in both melanoma and some renal cell carcinoma cell lines but was absent in other renal cell lines (such as KU-2) and in Daudi lymphoma cells. This emphasizes cell differences, suggesting that cell-restricted transcriptional regulators may interact with IFN-stimulated pathways to induce expression of the K12 gene and other ISGs.
Amphiphysin 1 coordinates membrane microdomains and plays a role in clatharin-mediated apoptosis. (56) Amphiphysin, expressed to a 3 times greater amount in WM9 than in WM35, has also been characterized as a substrate for both cyclin-dependent kinase 5 and cyclin B kinase during mitosis in both yeast and vertebrates. (57) This phosphorylation could play a role in modulating cell proliferation. ISG20, increased 10 times more by IFN-b than by IFN-a2 in WM9 cells, was associated with the apoptosis-related nuclear body containing the PML gene product. (58) The PML protein sensitizes cells to apoptosis by death ligands through interaction with RelA/p65 and thus suppresses NF-kB survival pathways. (59) Recently, ISG20 was identified as an RNase with single-stranded exonuclease activity. (58) Whether it has a selective effect on specific mRNAs, thus mediating greater apoptosis effects and antiproliferative effects, has yet to be determined.
Coordinated induction of the novel ubiquitin family ISGs, ISG15, USP18, and UBE1L or UBE-2L6, may be important for control of cell growth suppression and apoptosis. (23, 37, (60) (61) (62) UBE-1L was identified as an activating enzyme for ISG15. (63) ISG15 is conjugated to intracellular proteins via an isopeptide bond similar to ubiquitin, (60) (61) (62) may influence IFN signaling, and is also secreted. (23, (60) (61) (62) The UBE-2L6 gene, homologous to yeast gene UBC9 that is critical in progression from G 2 to M, encodes UbcH8, a ubiquitin-conjugating enzyme that belongs a multigene family with functional redundancy. (37) USP18, an ISG15-specific 17 protease, (23) is crucial for cellu- lar balance of ISG15-conjugated proteins. USP18 2/2 mice have massive accumulation of ISG15 conjugates and cellular necrosis. (64) The identification of new IFN-regulated genes by cDNA and oligonucleotide arrays will continue to provide new insights into host response to IFN treatment and may lead to more effective use of IFNs. (12, 21, 26, 52, 65) Future correlations of array profiles from patients may bring about predictions of melanoma invasiveness or clinical outcome. (66) Better definition of the mechanism causing the differing biologic effects of IFN-b may also illuminate important new signal transduction events. Little is known about the biologic and cellular effects of many of the genes that are substantially augmented in expression by IFNs. Despite their broad activity in treatment of viral diseases, cancer, and multiple sclerosis, the diversity of genes induced suggests that the full therapeutic potential of IFNs is yet to be realized.
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